Skip to main navigation Skip to search Skip to main content

Toward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force

  • Alina Markova
  • , Stephanie J. Lee
  • , Badri Modi
  • , Emily Baumrin
  • , Rachel K. Rosenstein
  • , Eric R. Tkaczyk
  • , Julia S. Lehman
  • , Yoshihiro Inamoto
  • , Paul A. Carpenter
  • , Kirk R. Schultz
  • , Joseph A. Pidala
  • , Paul Martin
  • , Iskra Pusic
  • , Sencer Goklemez
  • , Christian Stockmann
  • , Iago Pinal-Fernandez
  • , Sophie Paczesny
  • , Andrew Harris
  • , Doris M. Ponce
  • , Noa G. Holtzman
  • Najla El Jurdi, Steven Z. Pavletic, Edward W. Cowen
  • Memorial Sloan-Kettering Cancer Center
  • Cornell University
  • Fred Hutchinson Cancer Research Center
  • University of Washington
  • City of Hope National Med Center
  • University of Pennsylvania
  • Department of Veterans Affairs
  • Vanderbilt University
  • Mayo Clinic Rochester, MN
  • Fujita Health University
  • University of British Columbia
  • Moffitt Cancer Center
  • Washington University St. Louis
  • National Institutes of Health
  • University of Cincinnati
  • University of Zurich
  • Johns Hopkins University
  • Medical University of South Carolina
  • University of Miami

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The National Institutes of Health (NIH) chronic graft-versus-host disease (cGVHD) Consensus Project established response criteria that enabled clinical trials and facilitated regulatory approval of multiple therapies. Nonetheless, organ-specific assessments have limitations, particularly for severe sclerotic skin involvement. Cutaneous manifestations occur in approximately half of patients with chronic GVHD but are difficult to evaluate due to heterogeneous clinical features. To address these challenges, the NIH Consensus Skin Task Force convened from 2024 to 2025 to refine skin response measures for use in clinical trials. This report (1) summarizes current diagnosis and scoring of skin chronic GVHD, (2) reviews existing response assessments, (3) identifies gaps in their performance, (4) proposes refinements to the 2014 NIH skin response criteria, and (5) outlines future directions incorporating patient-reported outcomes, novel technologies, and biomarker research. Current NIH scoring relies on a 4-point body surface area (BSA) scale and a 3-point sclerosis features scale. While standardized, these measures have limited sensitivity to clinically meaningful change. Proposed refinements include: (1) separate BSA assessments for epidermal involvement and sclerotic features; (2) modification of sclerosis descriptors, with removal of impaired mobility and specification of GVHD-related ulceration, and addition of sclerosis-associated edema with or without erythema; and (3) replacement of the exploratory severity scale with two new clinician instruments. The Sclerosis Quality and Physical Signs scale (0 to 10) captures qualitative physical changes, while the Sclerosis Daily Function Impact scale (0 to 4) evaluates functional compromise. These proposed refinements aim to improve the accuracy, reproducibility, and clinical relevance of skin chronic GVHD assessments, strengthening trial endpoints and patient care.

Original languageEnglish
Pages (from-to)644.e1-644.e19
JournalTransplantation and Cellular Therapy
Volume32
Issue number6
DOIs
StatePublished - Jun 2026

Keywords

  • Chronic GVHD response
  • Chronic cutaneous GVHD
  • Chronic graft-versus-host disease
  • Epidermal GVHD
  • Sclerotic GVHD
  • Skin GVHD

Fingerprint

Dive into the research topics of 'Toward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force'. Together they form a unique fingerprint.

Cite this